Bydureon exenatide once weekly regulatory update

FDA accepted an NDA resubmission from Amylin for Type II diabetes candidate once-weekly Bydureon exenatide. The agency designated the NDA a Class 2 resubmission, with a PDUFA date of Jan. 28, 2012. Th...